Analysis of short-term effects of FOLFOX4 in the treatment of advanced gastric carcinoma
- Author:
Peng XU
1
Author Information
1. Department of Surgery
- Publication Type:Journal Article
- Keywords:
Adverse drug reaction reporting systems;
Drug therapy, combination;
Stomach neoplasms
- From:
Tumor
2007;27(8):660-662
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the short-term efficacy and the safety of FOLFOX4 regimen for patients with advanced gastric carcinoma (AGC). Methods: All of the 32 AGC patients were assessable for the safety analysis and for response. Oxaliplatin (85 mg/m2) was infused over 2 h on day 1. The leucovorin (LV, 200 mg/m2) was infused for 2 h followed by bolus (400 mg/m2) and a 22 h infusion (600 mg/m2) of 5-FU on day 1 and day 2. The treatment was repeated every 2 weeks and twice treatment as one cycle. All the patients received at least 4 cycles of treatment. Results: Of the 32 patients, 1 patient had complete response and 14 patients had partial responses (overall response rate 46.9%, 15/32). The median time to progression (TTP) was 5.6 months. The major adverse effects were mild peripheral neuropathy, nausea/vomiting and neutropenia. No treatment-related death occurred. Conclusion: FOLFOX4 regimen has good efficacy on AGC with relatively light toxicity. It could be selected as chemotherapy regimen for AGC patients.
